Chimeric Therapeutics is trading at A$0.06 (+5.77%) as investor attention remains fixed on a potential corporate transaction following the company's recent strategic review.
- The upward movement appears tied to ongoing speculation regarding value-creating options for the small-cap biotech firm, rather than a new same-day announcement.
- Market sentiment continues to be driven by the July 1 strategic review and a recent board reshuffle, which are being viewed as key catalysts for the stock.